CytoReason Expands Its Reach in Asia, Forging Commercial Alliance with Helixrus to Leverage Machine Learning in Drug Development for Korean Drugmakers

TEL AVIV, Israel and SEOUL, South Korea, April 12, 2022 /PRNewswire/ — CytoReason, a leading developer of computational disease models for efficient drug discovery and development, announced today the signing of a commercial partnership with Helixrus, a leading Korean company focused on…

Leave a Reply

Your email address will not be published.